SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects

Nature Reviews Endocrinology

Volumn 8, Issue 8, 2012, Pages 495-502

  Ferrannini, Ele ^a   Solini, Anna ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; BLOOD PRESSURE REGULATION; CANCER RISK; CELL FUNCTION; DIABETES MELLITUS; DRUG MECHANISM; DRUG TOLERABILITY; ENERGY BALANCE; GLUCOSE ABSORPTION; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; UPREGULATION; UROGENITAL TRACT INFECTION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MICE, KNOCKOUT; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84864283226     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.243     Document Type: Review

References (71)

1. DeFronzo, R. A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795 (2009).
2. Meier, J. J., Ueberberg, S., Korbas, S. & Schneider, S. Diminished glucagon suppression after β cell reduction is due to impaired α cell function rather than an expansion of α cell mass. Am. J. Physiol. Endocrinol. Metab. 300, E717-E723 (2011).
3. Ferrannini, E. The stunned beta cell: a brief history. Cell Metab. 11, 349-352 (2010).
4. Schwanstecher, C. & Schwanstecher, M. Targeting type 2 diabetes. Handb. Exp. Pharmacol. 203, 1-33 (2011).
5. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107 (2011).
6. Kaneto, H., Katakami, N., Matsuhisa, M. & Matsuoka, T. A. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm. 2010, 43892 (2010).
7. Jonas, J. C. et al. Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. Diabetes Obes. Metab. 11 (Suppl. 4), 65-81 (2009).
8. Leibowitz, G. et al. Glucose regulation of β cell stress in type 2 diabetes. Diabetes Obes. Metab. 12 (Suppl. 2), 66-75 (2010).
9. Wright, E. M., Loo, D. D. & Hirayama, B. A. Biology of human sodium glucose transporters. Physiol. Rev. 91, 733-794 (2011).
10. Hummel, C. S. et al. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300, C14-C21 (2011).
11. Banerjee, S. K. et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J. Mol. Cell. Cardiol. 49, 683-692 (2010).
12. Li, H., Gu, Y., Zhang, Y., Lucas, M. J. & Wang, Y. High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro. J. Soc. Gynecol. Investig. 11, 75-81 (2004).
13. von Lewinski, D. et al. Glucose transporter mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59, 1020-1028 (2010).
14. Takata, K. Glucose transporters in the transepithelial transport of glucose. J. Electron Microsc. 45, 275-284 (1996).
15. Vallon, V. et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22, 104-112 (2011).
16. Wright, E. M., Hirayama, B. A. & Loo, D. F. Active sugar transport in health and disease. J. Intern. Med. 261, 32-43 (2007).
17. Ruhnau, B., Faber, O. K., Borch-Johnsen, K. & Thorsteinsson, B. Renal threshold for glucose in non insulin dependent diabetic patients. Diabetes Res. Clin. Pract. 36, 27-33 (1997).
18. Farber, S. J., Berger, E. Y. & Earle, D. P. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J. Clin. Invest. 30, 125-129 (1951).
19. Elsas, L. J. & Rosenberg, L. E. Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J. Clin. Invest. 48, 1845-1854 (1969).
20. Sha, S. et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 13, 669-672 (2011).
21. Maurer, T. S. et al. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J. 13, 576-584 (2011).
22. Mogensen, C. E. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28, 101-109 (1971).
23. Rahmoune, H. et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non insulin dependent diabetes. Diabetes 54, 3427-3434 (2005).
24. Jurczak, M. J. et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60, 890-898 (2011).
25. Pontoglio, M. et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359-365 (2000).
26. Yamagata, K. et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458 (1996).
27. Schmidt, C., Höcherl, K. & Bucher, M. Regulation of renal glucose transporters during severe inflammation. Am. J. Physiol. Renal Physiol. 292, F804-F811 (2007).
28. Bautista, R. et al. Angiotensin II dependent increased expression of Na+-glucose cotransporter in hypertension. Am. J. Physiol. Renal Physiol. 286, F127-F133 (2004).
29. Ly, J. P. et al. The Sweet Pee model for Sglt2 mutation. J. Am. Soc. Nephrol. 22, 113-123 (2011).
30. Wright, E. M., Turk, E. & Martin, M. G. Molecular basis for glucose-galactose malabsorption. Cell Biochem. Biophys. 36, 115-121 (2002).
31. Calado, J., Soto, K., Clemente, C., Correia, P. & Rueff, J. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum. Genet. 114, 314-316 (2004).
32. Calado, J. et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol. Dial. Transplant. 23, 3874-3879 (2008).
33. Calado, J. et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 69, 852-855 (2006).
34. Oemar, B. S., Byrd, D. J. & Brodehl, J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin. Nephrol. 27, 156-160 (1987).
35. Gopalakrishnan, A., Kumar, M., Krishnamurthy, S., Sakamoto, O. & Srinivasan, S. Fanconi-Bickel syndrome in a 3 year old Indian boy with a novel mutation in the GLUT2 gene. Clin. Exp. Nephrol. 15, 745-748 (2011).
36. Ehrenkranz, J. R., Lewis, N. G., Kahn, C. R. & Roth, J. Phlorizin: a review. Diabetes Metab. Res. Rev. 21, 31-38 (2005).
37. Ellsworth, B. A. et al. Aglycone exploration of C arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. Bioorg. Med. Chem. Lett. 18, 4770-4773 (2008).
38. Meng, W. et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145-1149 (2008).
39. Nomura, S. et al. Discovery of canagliflozin, a novel C glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355-6360 (2010).
40. Obermeier, M. et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS 512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab. Dispos. 38, 405-414 (2010).
41. Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W. & List, J. F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33, 2217-2224 (2010).
42. Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet 375, 2223-2233 (2010).
43. Wilding, J. P. et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32, 1656-1662 (2009).
44. Kasichayanula, S. et al. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. Diabetes Obes. Metab. 13, 770-773 (2011).
45. Kasichayanula, S. et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes. Metab. 13, 47-54 (2011).
46. Hussey, E. K. et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J. Clin. Pharmacol. 50, 636-646 (2010).
47. Fujimori, Y. et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327, 268-276 (2008).
48. Kashiwagi, A. et al. Ipragliflozin improved glycemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study [abstract]. Diabetologia 54 (Suppl. 1), S68, a149 (2011).
49. Seman, L. et al. ENCORE: efficacy and safety of BI 10773, a new sodium glucose co transporter 2 (SGLT 2) inhibitor, in type 2 diabetes patients inadequately controlled on metformin [abstract]. Diabetologia 54 (Suppl. 1), S67, a147 (2011).
50. Powell, D. et al. Single doses of LX4211, a dual inhibitor of SGLT1 and SGLT2, improves parameters of glycaemic control and increases GLP 1 and PYY in patients with type 2 diabetes [abstract]. Diabetologia 54 (Suppl. 1), S69, a150 (2011).
51. Isaji, M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int. Suppl. 120, S14-S19 (2011).
52. Yamamoto, K. et al. TS 071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycemic activity. Br. J. Pharmacol. 164, 181-191 (2011).
53. Yao, C. H. et al. Discovery of novel N β D xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J. Med. Chem. 54, 166-178 (2011).
54. Kadokura, T. et al. The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ipragliflozin (ASP1941) in Japanese type 2 diabetes mellitus patients [abstract]. Diabetologia 54 (Suppl. 1), S346, a847 (2011).
55. Abdul-Ghani, M. A., Norton, L. & DeFronzo, R. A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev. 32, 515-531 (2011).
56. Piya, M. K., Tahrani, A. A. & Barnett, A. H. Emerging treatment options for type 2 diabetes. Br. J. Clin. Pharmacol. 70, 631-644 (2010).
57. Ghosh, R. K., Ghosh, S. M., Chawla, S. & Jasdanwala, S. A. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J. Clin. Pharmacol. http://dx.doi.org/10.1177/0091270011400604
58. Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
59. Osorio, H. et al. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J. Nephrol. 23, 541-546 (2010).
60. Vallon, V., Richter, K., Blantz, R. C., Thomson, S. & Osswald, H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10, 2569-2576 (1999).
61. Hannedouche, T. P. et al. Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. Kidney Int. 37, 1126-1133 (1990).
62. Vervoort, G., Veldman, B., Berden, J. H., Smits, P. & Wetzels, J. F. Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion. Eur. J. Clin. Invest. 35, 330-336 (2005).
63. List, J. F., Woo, V., Morales, E., Tang, W. & Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32, 650-657 (2009).
64. Quiñones Galvan, A. et al. Effect of insulin on uric acid excretion in humans. Am. J. Physiol. 268, E1-E5 (1995).
65. Doblado, M. & Moley, K. H. Facilitative glucose transporter 9, a unique hexose and urate transporter. Am. J. Physiol. Endocrinol. Metab. 297, E831-E835 (2009).
66. Zhang, L., Feng, Y., List, J., Kasichayanula, S. & Pfister, M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes. Metab. 12, 510-516 (2010).
67. Lam, T. K. Neuronal regulation of homeostasis by nutrient sensing. Nat. Med. 16, 392-395 (2010).
68. Yu, A. S. et al. Functional expression of SGLTs in rat brain. Am. J. Physiol. Cell Physiol. 299, C1277-C1284 (2010).
69. FDA. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting, July 19, 2011 [online]. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM262994.pdf (2011).
70. Nauck, M. A. et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34, 2015-2022 (2011).
71. Johnston, S. S. et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 34, 1164-1170 (2011).